יחס שווי פעילות לרווח לפני ריבית, מסים ופחת: Advanced Biomed Corp (ADVB)

Advanced Biomed Inc (ADVB) generates revenue through the implementation of tumor marker detection systems that enable rapid adjustments to therapy regimens. Automated microfluidic devices replace manual laboratory labor, representing state-of-the-art robotics. The project is currently focused on R&D to create affordable tumor screening. The EV/EBITDA ratio stands at 0.00, which is clearly reflected in the company's price chart.

For Advanced Biomed Inc (ADVB), which is developing high-tech AI-based cancer screening, the company's EV/EBITDA multiple allows for a correlation between the total enterprise value, including debt load, and its operating profit before taxes and amortization. The trend of this metric helps investors determine the degree of asset overvaluation and assess the company's financial stability amidst its expansion into the global diagnostics market.